Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1
A roundup of investment news.
Focusing on stocks with the most visible cash flows has been a winning strategy, and this screen can find them.
Who's in front heading 'round the bend?
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
This screen finds stocks that would make it into Morningstar's Wide-Moat Focus strategy.
Plus, Vanguard says 401(k) investors stayed the course in 2008, Macquarie Group buys Delaware Investments, more leveraged ETF warnings, and more.
Many funds' fortunes have turned amid these stocks' volatility.
The drugmaker faces less long-term volatility as the focus shifts to steady businesses.